Volvo EX90 Electric SUV Will Feature Seoul Semiconductor’s SunLike LED Lighting
18.4.2023 16:00:00 EEST | Business Wire | Press release
Seoul Semiconductor Co., Ltd. (KOSDAQ:046890), a global optical semiconductor company, has announced that the new Volvo EX90 Electric SUV will feature its SunLike LED lights. This is the first application of the SunLike technology with sun spectrum in production vehicles.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230418005618/en/
Volvo EX90 featuring the SunLike technology (Left) / Comparative graph of color gamuts between SunLike and general LEDs (Right) (Graphic: Business Wire)
SunLike, developed and mass-produced by Seoul Semiconductor for the first time in the world, is a healthy light technology that replicates natural light, protecting the 24-hour biological cycle of a human body. For the past five years, Seoul Semiconductor carried out multiple clinical trials with Harvard University in the United States, the University of Basel in Switzerland, and Seoul National University in Korea, confirming that the use of the solar spectrum, SunLike, can make improvements in myopia, regenerate cells, improve memory, and replicate natural colors.
NEARSIGHTEDNESS IMPROVEMENT
Not all lights are the same, and not all lightings are the same. The closer it is to natural light, the better it is. Light is a mass of particles with energy, so the longer our eyes are exposed to high levels of blue light with high energy, there is a greater chance of damaging our photoreceptor cells and developing myopia. This is why children in Asia who spend more time indoors than outdoors under natural light have a high prevalence of myopia.
According to the “Recovery From Form-Deprivation Myopia in Chicks Is Dependent Upon the Fullness and Correlated Color Temperature of the Light Spectrum(2020)” by Singapore Eye Research Institute (SERI), myopia can be improved by using SunLike.
CELL REPRODUCTION
Natural light affects sleep as well. Evening sunlight promotes the secretion of melatonin which helps to sleep. They say more than 70% of our 60 trillion body cells regenerate while we sleep. Seoul Semiconductor confirmed through the “Effect of daylight LED on visual comfort, melatonin, mood, waking performance and sleep (2019)” conducted by the University of Basel in Switzerland that SunLike lighting improves sleep quality compared to conventional LEDs.
MEMORY IMPROVEMENT
Getting a good night sleep reduces the possibility of building up toxins in the brain, improving memory and concentration. Seoul Semiconductor confirmed through the “Daytime Exposure to Short Wavelength-Enriched Light Improves Cognitive Performance in Sleep-Restricted College-Aged Adults (2021)” conducted by Harvard Medical School that problem-solving skills improved by 5% and speed increased by 3.2 folds when SunLike lighting was used.
COLOR REPLICATION
Conventional LED with CRI 90 have a 90% color gamut of 14 colors in high CRI 90 (sunlight 100). However, SunLike has a 95% color gamut of all 99 colors. This means that it is closest to the color seen under natural sunlight.
According to Dan Fidgett, Volvo’s head of materials and colors, “By utilising the spectrum of light emitted from the SunLike LEDs, the progressive materials and interior design of the Volvo EX90 stand out more clearly and without colour distortion” Fidgett also added, “Bringing in SunLike LEDs to the interior of the Volvo EX90 is another illustration of our ambition to bring in innovative technology to deliver a renewed premium in-car experience for our customers”.
For all interior light fixtures of Volvo EX90, SunLike will be installed. Already widely used by large museums and art galleries around the world, SunLike LEDs have been used to reveal the color and texture of Pompeii ruins’ murals in Italy.
N. Kobayashi, SunLike’s key developer and Seoul Semiconductor’s technical advisor (former CEO of TMAT), explains, “SunLike is a differentiated, high-quality ‘healthy lighting’ that has all the benefits of natural light. It is widely being used in various places, such as residential spaces where people rest, hospitals that lack outdoor activities, schools where concentration and vision health are important, horticultural greenhouses that require light, etc”.
In addition to Volvo EX90, SunLike will also equip ‘Polestar 3’ which shares the same technology base.
About Seoul Semiconductor
Seoul Semiconductor is the world’s second-largest global LED manufacturer, a ranking excluding the captive market, and has more than 18,000 patents. Based on a differentiated product portfolio, Seoul offers a wide range of technologies, and mass produces innovative LED products for indoor and outdoor lighting, automotive, IT products, such as mobile phones, computer displays, and other applications, as well as the UV area. Seoul’s world’s first development and mass production products are becoming the LED industry standard and leading the global market with a package-free LED, WICOP; a high-voltage AC-driven LED, Acrich; an LED with 10X the output of a conventional LED, nPola; a cutting edge ultraviolet clean technology LED, Violeds; an all-direction light emitting technology, filament LED; a natural sun spectrum LED, SunLike; and more. For more information, please visit www.seoulsemicon.com/en, YouTube, LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230418005618/en/
Contact information
Seoul Semiconductor Co., Ltd.
Jinseop Jung
+82-1566-2771
jjs8732@seoulsemicon.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
